MedTrace Logo

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

NCT00406640 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 595

Last updated 2023-12-28

Study results available
· View outcomes & findings →

Summary

Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability of DVS SR versus escitalopram in women with major depressive disorder (MDD) who are postmenopausal.

Conditions

  • Depression
  • Depressive Disorder
  • Depressive Disorder, Major

Interventions

DRUG

Desvenlafaxine succinate sustained-release (DVS SR)

flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.

DRUG

Escitalopram

Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-02-29
Completion
2008-10-31

Countries

  • United States
  • Argentina
  • Chile
  • Colombia
  • Mexico
  • Peru

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00406640 on ClinicalTrials.gov